Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma
Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Clinical Hypothesis:
It is expected that by removing chemotherapy and adding ancestim to the mobilization scheme
in most of the subjects sufficient PBPC will be harvested with a minimum of toxicity and side
effects.
Phase:
Phase 2
Details
Lead Sponsor:
Aalborg Universitetshospital Aalborg University Hospital
Collaborators:
Amgen Helsinki University Central Hospital Herlev Hospital Nordic Lymphoma Group Oslo University Hospital Rigshospitalet, Denmark Turku University Hospital Umeå University University Hospital, Linkoeping